Stocktoria
Candel Therapeutics, Inc. CADL
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-07-27
Candel Therapeutics, Inc. statistics & valuation
Market cap$717.3M
P / B13.8×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | — | — | — | -27777.6% | -20580.8% |
| Net margin | — | — | — | -15035.2% | -28899.2% |
| FCF margin | — | — | — | -26172.8% | -19242.4% |
| Return on assets | -30.5% | -51.6% | -92.1% | -24.2% | -40.5% |
| Return on equity | -73.5% | -83.2% | -297.7% | -39.4% | -56.3% |
| Debt / equity | — | 0.03× | 0.91× | — | 0.01× |
| Current ratio | 13.49 | 2.77 | 2.59 | 12.81 | 15.84 |
| Revenue growth | — | — | — | 0.0% | 0.0% |
Source: SEC EDGAR filings · CIK 0001841387 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.